Delving into the Latest Updates on Rilematovir with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

RSV F protein

Mechanism

Respiratory syncytial virus F protein inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Acute lower respiratory tract infectionAcute respiratory infectionsAcute upper respiratory infection+ [3]

Originator Organization

Johnson & Johnson

Active Organization-

Inactive Organization

Janssen Research & Development LLCJanssen Sciences Ireland ULCJanssen Sciences Ireland UC

+ [1]

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationBreakthrough Therapy (CN)

Login to view timeline

Structure

Molecular FormulaC21H20ClF3N4O3S

InChIKeyGTQTUABHRCWVLL-UHFFFAOYSA-N

CAS Registry1383450-81-4

ABSTRACTRespiratory syncytial virus (RSV) is a leading cause of acute respiratory infection amongst all ages, causing a significant global health burden. Preventative and therapeutic options for RSV infection have long been under development, and recently, several widely‐publicised vaccines targeting older adult and maternal populations have become available. Promising monoclonal antibody (mAb) and antiviral (AV) therapies are also progressing in clinical trials, with the prophylactic mAb nirsevimab recently approved for clinical use in infant populations. A systematic review on current progress in this area is lacking. We performed a systematic literature search (PubMed, Embase, Web of Science, ClinicalTrials.gov, EudraCT, ANZCTR—searched Nov 29th, 2023) to identify studies on all RSV‐specific mAbs and AV therapies that has undergone human clinical trials since year 2000. Data extraction focused on outcomes related to the therapeutic efficacy and safety of the intervention on trial, and all studies were graded against the OCEBM Levels of Evidence Table. Results from 59 studies were extracted, covering efficacy and safety data on six mAbs (motavizumab, motavizumab‐YTE, nirsevimab, ALX‐0171, suptavumab, clesrovimab) and 12 AV therapies (ALN‐RSV01, RSV604, presatovir, MDT‐637, lumicitabine, IFN‐α1b, rilematovir, enzaplatovir, AK0529, sisunatovir, PC786, EDP‐938). Of the mAbs reviewed, nirsevimab and clesrovimab hold considerable promise. The timeline for RSV‐specific AV availability is less advanced, although EDP‐938 and AK0529 have reported promising phase 2 efficacy and safety data. Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development.Trial RegistrationPROSPERO registration: CRD42022376633

01 Jul 2024·Pediatric Drugs

CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus

Article

Author: Stoeva, Tatyana ; Liese, Johannes ; Gamil, Mohamed ; Rusch, Sarah ; Deleu, Sofie ; Sánchez, Beatriz López ; Huntjens, Dymphy ; Luz, Kleber ; Stevens, Marita ; Chen, Bohang ; Toh, Teck-Hock ; Calvo, Cristina ; Vijgen, Leen ; Lin, Chien-Yu ; Nemeth, Agnes ; Ferrero, Fernando ; Gijón, Manuel ; Baguet, Tristan ; Leipoldt, Illse ; Bertzos, Kristi ; Natalini, Silvina

BACKGROUNDRespiratory syncytial virus (RSV) causes significant morbidity and mortality in children aged ≤ 5 years and adults aged ≥ 60 years worldwide. Despite this, RSV-specific therapeutic options are limited. Rilematovir is an investigational, orally administered inhibitor of RSV fusion protein-mediated viral entry.OBJECTIVETo establish the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir (low or high dose) in children aged ≥ 28 days and ≤ 3 years with RSV disease.METHODSCROCuS was a multicenter, international, double-blind, placebo-controlled, randomized, adaptive phase II study, wherein children aged ≥ 28 days and ≤ 3 years with confirmed RSV infection who were either hospitalized (Cohort 1) or treated as outpatients (Cohort 2) were randomized (1:1:1) to receive rilematovir (low or high dose) or placebo. Study treatment was administered daily as an oral suspension from days 1 to 7, with dosing based on weight and age groups. The primary objective was to establish antiviral activity of rilematovir by evaluating the area under the plasma concentration-time curve of RSV viral load in nasal secretions from baseline through day 5. Severity and duration of RSV signs and symptoms and the safety and tolerability of rilematovir were also assessed through day 28 (± 3).RESULTSIn total, 246 patients were randomized, treated, and included in the safety analysis population (Cohort 1: 147; Cohort 2: 99). Of these, 231 were included in the intent-to-treat-infected analysis population (Cohort 1: 138; Cohort 2: 93). In both cohorts, demographics were generally similar across treatment groups. In both cohorts combined, the difference (95% confidence interval) in the mean area under the plasma concentration-time curve of RSV RNA viral load through day 5 was - 1.25 (- 2.672, 0.164) and - 1.23 (- 2.679, 0.227) log₁₀ copies∙days/mL for the rilematovir low-dose group and the rilematovir high-dose group, respectively, when compared with placebo. The estimated Kaplan-Meier median (95% confidence interval) time to resolution of key RSV symptoms in the rilematovir low-dose, rilematovir high-dose, and placebo groups of Cohort 1 was 6.01 (4.24, 7.25), 5.82 (4.03, 8.18), and 7.05 (5.34, 8.97) days, respectively; in Cohort 2, estimates were 6.45 (4.81, 9.70), 6.26 (5.41, 7.84), and 5.85 (3.90, 8.27) days, respectively. A similar incidence of adverse events was reported in patients treated with rilematovir and placebo in Cohort 1 (rilematovir: 61.9%; placebo: 58.0%) and Cohort 2 (rilematovir: 50.8%; placebo: 47.1%), with most reported as grade 1 or 2 and none leading to study discontinuation. The study was terminated prematurely, as the sponsor made a non-safety-related strategic decision to discontinue rilematovir development prior to full recruitment of Cohort 2.CONCLUSIONSData from the combined cohort suggest that rilematovir has a small but favorable antiviral effect of indeterminate clinical relevance compared with placebo, as well as a favorable safety profile. Safe and effective therapeutic options for RSV in infants and young children remain an unmet need.CLINICAL TRIAL REGISTRATIONEudraCT Number: 2016-003642-93; ClinicalTrials.gov Identifier: NCT03656510. First posted date: 4 September, 2018.

01 Oct 2023·Clinical Microbiology and Infection

A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection

Article

Author: Napora, Piotr ; Luz, Kleber ; Aggarwal, Naresh ; Bertzos, Kristi ; Gupta, Anil ; Petrova, Galina ; Guzman Romero, Ana Karla ; Vijgen, Leen ; Draghi, Jorge ; Scott, Jane ; Stevens, Marita ; Pullman, John ; Ianus, Juliana ; Rusch, Sarah ; Huntjens, Dymphy ; Nilsson, Anna C ; Sinha, Rekha

OBJECTIVESTo assess the antiviral effect, clinical outcomes, and safety of the respiratory syncytial virus (RSV) fusion inhibitor rilematovir in non-hospitalized RSV-infected adults.METHODSThis phase 2a, double-blind, multicentre study randomly assigned RSV-positive adult outpatients ≤5 days from symptom onset 1:1:1 to receive rilematovir 500 mg, 80 mg, or placebo once-daily for 7 days. Antiviral effect was assessed by RSV RNA viral load (VL), measured by quantitative RT-PCR, and Kaplan-Meier (KM) estimates of time to undetectable VL. Clinical course was assessed by KM estimates of median time to resolution of key RSV symptoms assessed through patient-reported outcomes.RESULTSRSV-positive patients (n = 72) were randomly assigned; 66 had confirmed RSV infection and received rilematovir 500 mg (n = 23), 80 mg (n = 21) or placebo (n = 22). Differences versus placebo in mean RSV RNA VL area under the curve (90% CI) through days 3, 5 and 8, respectively, were 0.09 (-0.837; 1.011), -0.10 (-2.171; 1.963), and -1.03 (-4.746; 2.682) log₁₀ copies.day/mL for rilematovir 500 mg, and 1.25 (0.291; 2.204), 2.53 (0.430; 4.634), and 3.85 (0.097; 7.599) log₁₀ copies.day/mL for rilematovir 80 mg. KM estimates of median (90% CI) time-to-first confirmed undetectable VL were 5.9 (3.85; 6.90), 8.0 (6.86; 12.80) and 7.0 (6.62; 10.88) days and 5.7 (2.93; 7.01), 8.1 (6.74; 12.80) and 7.9 (6.62; 11.74) days in patients with symptom onset ≤3 days, for rilematovir 500 mg, 80 mg, and placebo, respectively. KM estimates of median (90% CI) time to resolution of key RSV symptoms were 7.1 (5.03; 11.43), 7.6 (5.93; 8.32), and 9.6 (5.95; 14.00) days for rilematovir 500 mg, 80 mg, and placebo, respectively; and in patients with symptom onset ≤3 days, median 8.0, 7.6, and 11.8 days, respectively.DISCUSSIONRilematovir use, initiated early, suggests a potential clinical benefit in RSV-infected adults, with data supporting development of RSV therapeutic options.TRIAL REGISTRATIONThis study is registered with clinicaltrials.gov (NCT03379675).

100 Deals associated with Rilematovir

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15672

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Syncytial Virus Infections	Phase 3	RU	Janssen Research & Development LLC	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	RU	Janssen Research & Development LLC	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	SK	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	SK	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	MX	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	EE	Janssen Research & Development LLC	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	US	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	EE	Janssen Research & Development LLC	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	MX	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021
Respiratory Syncytial Virus Infections	Phase 3	US	Johnson & Johnson (China) Investment Ltd.	06 Sep 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03656510 (CTgov)	Phase 2	Acute lower respiratory tract infection \| Respiratory Syncytial Virus Infections	246	placebo+JNJ-53718678 (Cohorts 1 and 2: Placebo)	rmpubankhe(ztlolcjyvf) = keubjwuazo hzrradexqp (gouhneyfml, knezdcindu - yqhobwzgal) View more	-	21 Sep 2023
				JNJ-53718678 (Cohorts 1 and 2: JNJ-53718678 Low Dose)	rmpubankhe(ztlolcjyvf) = zbizdfdgdb hzrradexqp (gouhneyfml, bdogcluyzi - fmjmumigic) View more
NCT03379675 (Pubmed)	Phase 2	Respiratory Syncytial Virus Infections	72	Rilematovir 500 mg	(kwccimwsqp) = omnuiguxoz gyfnlvhyxn (ydaukpjokl, -0.837 to 1.011) View more	-	06 Jul 2023
				Rilematovir 80 mg	(kwccimwsqp) = xetfoijjpe gyfnlvhyxn (ydaukpjokl, -2.171 to 1.963) View more
NCT04978337 (PRIMROSE, CTgov)	Phase 2	Pneumonia due to respiratory syncytial virus	5	placebo+rilematovir (Placebo)	mxmhlmbtou(azbceltqyt) = elfyhspwgg zdnilkjtou (bghnrsaljq, jqoiyzozoc - evifbsjhwf) View more	-	21 Apr 2023
				Rilematovir (Rilematovir 250 mg Bid)	sakfiuhyuq(cuszgaftih) = droaaqimtv xxyibbyfwa (xuqlyludnx, emwzahluok - jcjtygodui) View more
NCT04056611 (FREESIA, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	3	rilematovir	zfpwggcixc(vjodtcurek) = mvysrrcxut opuvjlccja (oloimcrnjx, bcgkowrgur - hzefcpqeqx) View more	-	14 Apr 2023
NCT04583280 (DAISY, CTgov)	Phase 3	Acute lower respiratory tract infection \| Respiratory Syncytial Virus Infections	28	Placebo (Placebo)	lrtxppnjjz(plnpnlcxaq) = vymaseypep hjodhaqnrs (jcdjxttslx, retodxuhrw - erpgdmzjgf) View more	-	10 Apr 2023
				Rilematovir X mg/kg (Rilematovir)	lrtxppnjjz(plnpnlcxaq) = vdimutpaci hjodhaqnrs (jcdjxttslx, gsepzyzgbp - mfmuszyldp) View more
NCT03379675 (CTgov)	Phase 2	Respiratory Syncytial Virus Infections	72	JNJ-53718678 500 mg (Treatment A: JNJ-53718678 500 mg)	ajvhjwguzl(daevzlbilf) = vmpqxfbvud fyvgouzgfq (lnsgoxiwdg, mqyuchvyhd - sbwghkxfgg) View more	-	28 Jun 2022
				Placebo+JNJ-53718678 80 mg (Treatment B: JNJ-53718678 80 mg + Placebo)	ajvhjwguzl(daevzlbilf) = vkxttuckwk fyvgouzgfq (lnsgoxiwdg, xrkkmzvpby - jfjyzvjldc) View more
NCT04068792 (CTgov)	Phase 2	Acute upper respiratory infection \| Acute lower respiratory tract infection \| Respiratory Syncytial Virus Infections	22	placebo+JNJ-53718678 (Placebo)	iiypcmuniy(tgcmgxpfil) = iprpvcukzl smqusvajap (qryrkqyjjl, bpjgvvrkoj - jgasewqffv) View more	-	08 Jun 2022
				JNJ-53718678 (JNJ-53718678)	iiypcmuniy(tgcmgxpfil) = azbguhpfmv smqusvajap (qryrkqyjjl, txxipuzmgh - kznqjbhlib) View more
EUCTR2014-005041-41-GB \| NCT02387606 (Pubmed \| Am J Trop Med Hyg) Manual	Phase 2	Respiratory Syncytial Virus Infections	69	JNJ-53718678	(mhcidptzxa) = tcobzsqwht xxabjxlepc (rhlcrutucx ) View more	Positive	24 Jul 2018
				Placebo	(mhcidptzxa) = evcrqahjeq xxabjxlepc (rhlcrutucx ) View more